AstraZeneca: Crestor experiences additional setbacks

Withdrawal from the European approval process by three member states represents additional obstacles for Crestor, heightens concerns over safety, and will undoubtedly slow revenue gains for AstraZeneca. Therefore, although forecast to achieve blockbuster sales of $3.8 billion in 2010, Crestor will fail to make as significant an impact on the anti-dyslipidemic market as Lipitor did upon launch.

Published By Datamonitor

eHealth: Italy has the highest penetration of online CME in Europe

Published By Datamonitor

HIV/AIDS: US diagnosis 'average' in top seven markets

Published By Datamonitor

Asthma: two-thirds of patients suffer persistently

Published By Datamonitor

Cancer therapies: cytotoxics rise and fall

Published By Datamonitor

Significant changes in store for growing HIV market

Worth $8 billion in 2006, the HIV market is expected undergo significant changes as it expands to an estimated $11.5 billion in 2016. Patent expiries on key drugs and product launches in new and existing classes are set to reshape the HIV treatment paradigm. One player set to lose out as its ageing HIV portfolio loses its patent protection is the current market leader, GlaxoSmithKline.

Published By Datamonitor

HIV market: set to undergo dramatic changes over next decade

Published By Datamonitor

Ovation Pharmaceuticals' Sabril recommended by FDA panel despite reports of visual field defect

Ovation Pharmaceuticals has announced that an FDA advisory committee has voted unanimously to recommend Sabril (vigabatrin) for the treatment of two severe forms of epilepsy. If approved, Sabril will be the first FDA-approved monotherapy for infantile spasms. However, low historic uptake in the EU and concerns regarding visual field defects suggest that the drug's commercial prospects are limited.

Published By Datamonitor

Wyeth: positive Aprela results bode well for planned portfolio strategy

Wyeth has announced new positive Phase III data for its menopause treatment Aprela. The potential blockbuster is well positioned to provide a unique approach to the treatment of menopausal symptoms in women at risk of developing osteoporosis, and assuming regulatory hurdles can be overcome, Aprela will help further maintain Wyeth's position as a leading women's health player.

Published By Datamonitor

Nycomed/Merck: Daxas deal will have limited financial impact

Nycomed and Merck & Co. have agreed to co-promote the novel COPD therapy Daxas, which recently gained a positive recommendation in the EU. While this collaboration boosts Daxas' commercial prospects in several European countries, as well as Canada, the drug is limited by its restricted patient potential.

Published By Datamonitor